nach oben

Erschienen in:

01.04.2015 | Research Article

Transcription factor decoy against stem cells master regulators, Nanog and Oct-4: a possible approach for differentiation therapy

verfasst von: Seyed Mohammad Ali Hosseini Rad, Taravat Bamdad, Majid Sadeghizadeh, Ehsan Arefian, Majid Lotfinia, Milad Ghanipour

Erschienen in: Tumor Biology | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Transcription factor decoys (TFDs) are exogenous oligonucleotides which can compete by cis-elements in promoters or enhancers for binding to TFs and downregulating gene expression in a specific manner. It is believed that tumor mass originates from cancer stem cells (CSCs) which the same with embryonic stem cells (ESCs) have the properties of both pluripotency and self-renewal (stemness). Many transcription factors such as Nanog, Oct-4, Sox2, Klf4, and Sall4 act as master regulators in the maintenance of stemness in both cell types. Differentiation therapy is based on this theory that by differentiation of CSCs, tumor mass can be eliminated with common cancer therapy methods. To our knowledge, the present study is the first report of a TFD approach against master regulator of stemness, Nanog, Oct-4, and Klf4, for downregulation purposes in P19 embryonic carcinoma stem cell. Different simple and complex decoys against Nanog, OCT-4, Sox2, and Klf4 were designed and used for this purpose. The results showed that the applied decoys especially Nanog-specific decoy decreased the expression of downstream genes.

Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet. 2007;8:173–84.CrossRefPubMed

Dass CR, Choong PF. Targeting of small molecule anticancer drugs to the tumour and its vasculature using cationic liposomes: lessons from gene therapy. Cancer Cell Int. 2006;6:17.CrossRefPubMedPubMedCentral

Kumar R, Dammai V, Yadava PK, Kleinau S. Gene targeting by ribozyme against TNF-alpha mRNA inhibits autoimmune arthritis. Gene Ther. 2005;12:1486–93.CrossRefPubMed

Wang DY, Lai BH, Sen D. A general strategy for effector-mediated control of RNA-cleaving ribozymes and DNA enzymes. J Mol Biol. 2002;318:33–43.CrossRefPubMed

Bielinska A, Shivdasani RA, Zhang LQ, Nabel GJ. Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. Science. 1990;250:997–1000.CrossRefPubMed

Penolazzi L, Lambertini E, Aguiari G, del Senno L, Piva R. Modulation of estrogen receptor gene expression in human breast cancer cells: a decoy strategy with specific PCR-generated DNA fragments. Breast Cancer Res Treat. 1998;49:227–35.CrossRefPubMed

Morishita R, Higaki J, Tomita N, Ogihara T. Application of transcription factor "decoy" strategy as means of gene therapy and study of gene expression in cardiovascular disease. Circ Res. 1998;82:1023–8.CrossRefPubMed

Khaled AR, Butfiloski EJ, Sobel ES, Schiffenbauer J. Use of phosphorothioate-modified oligodeoxynucleotides to inhibit NF-kappaB expression and lymphocyte function. Clin Immunol Immunopathol. 1998;86:170–9.CrossRefPubMed

Gao H, Xiao J, Sun Q, Lin H, Bai Y, Yang L, et al. A single decoy oligodeoxynucleotides targeting multiple oncoproteins produces strong anticancer effects. Mol Pharmacol. 2006;70:1621–9.CrossRefPubMed

10.

Morishita R, Gibbons GH, Horiuchi M, Ellison KE, Nakama M, Zhang L, et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci U S A. 1995;92:5855–9.CrossRefPubMedPubMedCentral

11.

Ahn JD, Kim CH, Magae J, Kim YH, Kim HJ, Park KK, et al. E2F decoy oligodeoxynucleotides effectively inhibit growth of human tumor cells. Biochem Biophys Res Commun. 2003;310:1048–53.CrossRefPubMed

12.

Suzuki J, Isobe M, Morishita R, Izawa A, Yamazaki S, Okubo Y, et al. E2F decoy suppresses E-selectin expression in murine cardiac allograft arteriopathy. Transplant Proc. 1999;31:2018–9.CrossRefPubMed

13.

Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi S, Mai JC, et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci U S A. 2003;100:4138–43.CrossRefPubMedPubMedCentral

14.

Zhang X, Liu P, Zhang B, Wang A, Yang M. Role of STAT3 decoy oligodeoxynucleotides on cell invasion and chemosensitivity in human epithelial ovarian cancer cells. Cancer Genet Cytogenet. 2010;197:46–53.CrossRefPubMed

15.

Takahashi T, Togo S, Kumamoto T, Watanabe K, Kubota T, Ichikawa Y, et al. Transfection of NF-kappaB decoy oligodeoxynucleotides into macrophages reduces murine fatal liver failure after excessive hepatectomy. J Surg Res. 2009;154:179–86.CrossRefPubMed

16.

Ohmori K, Takeda S, Miyoshi S, Minami M, Nakane S, Ohta M, et al. Attenuation of lung injury in allograft rejection using NF-kappaB decoy transfection-novel strategy for use in lung transplantation. Eur J Cardiothorac Surg. 2005;27:23–7.CrossRefPubMed

17.

Kawamura I, Morishita R, Tsujimoto S, Manda T, Tomoi M, Tomita N, et al. Intravenous injection of oligodeoxynucleotides to the NF-kappaB binding site inhibits hepatic metastasis of M5076 reticulosarcoma in mice. Gene Ther. 2001;8:905–12.CrossRefPubMed

18.

Chae YM, Park KK, Lee IK, Kim JK, Kim CH, Chang YC. Ring-Sp1 decoy oligonucleotide effectively suppresses extracellular matrix gene expression and fibrosis of rat kidney induced by unilateral ureteral obstruction. Gene Ther. 2006;13:430–9.CrossRefPubMed

19.

Park JH, Jo JH, Kim KH, Kim SJ, Lee WR, Park KK, et al. Antifibrotic effect through the regulation of transcription factor using ring type-Sp1 decoy oligodeoxynucleotide in carbon tetrachloride-induced liver fibrosis. J Gene Med. 2009;11:824–33.CrossRefPubMed

20.

Alper O, Bergmann-Leitner ES, Abrams S, Cho-Chung YS. Apoptosis, growth arrest and suppression of invasiveness by CRE-decoy oligonucleotide in ovarian cancer cells: protein kinase a downregulation and cytoplasmic export of CRE-binding proteins. Mol Cell Biochem. 2001;218:55–63.CrossRefPubMed

21.

Liu WM, Scott KA, Shahin S, Propper DJ. The in vitro effects of CRE-decoy oligonucleotides in combination with conventional chemotherapy in colorectal cancer cell lines. Eur J Biochem. 2004;271:2773–81.CrossRefPubMed

22.

Cho WH, Kim HT, Koo JH, Lee IK. Effect of AP-1 decoy using hemagglutinating virus of Japan-liposome on the intimal hyperplasia of the autogenous vein graft in mongrel dogs. Transplant Proc. 2006;38:2161–3.CrossRefPubMed

23.

Holschermann H, Stadlbauer TH, Wagner AH, Fingerhuth H, Muth H, Rong S, et al. STAT-1 and AP-1 decoy oligonucleotide therapy delays acute rejection and prolongs cardiac allograft survival. Cardiovasc Res. 2006;71:527–36.CrossRefPubMed

24.

Nishitsuji H, Tamura Y, Fuse T, Habu Y, Miyano-Kurosaki N, Takaku H. Inhibition of HIV-1 replication by 5'LTR decoy RNA. Nucleic Acids Res Suppl. 2001;1:141–2.CrossRef

25.

Li MJ, Kim J, Li S, Zaia J, Yee JK, Anderson J, et al. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCr5 ribozyme, and a nucleolar-localizing TAR decoy. Mol Ther. 2005;12:900–9.CrossRefPubMed

26.

Zhang J, Yamada O, Sakamoto T, Yoshida H, Araki H, Murata T, et al. Inhibition of hepatitis C virus replication by pol III-directed overexpression of RNA decoys corresponding to stem-loop structures in the NS5B coding region. Virology. 2005;342:276–85.CrossRefPubMed

27.

Ward RJ, Dirks PB. Cancer stem cells: at the headwaters of tumor development. Annu Rev Pathol. 2007;2:175–89.CrossRefPubMed

28.

Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–11.CrossRefPubMed

29.

Sell S. Leukemia: stem cells, maturation arrest, and differentiation therapy. Stem Cell Rev. 2005;1:197–205.CrossRefPubMed

30.

Ivanova N, Dobrin R, Lu R, Kotenko L, Levorse J, DeCoste C, et al. Dissecting self-renewal in stem cells with RNA interference. Nature. 2006;44:533–8.CrossRef

31.

Dejosez M, Krumenacker JS, Zitur LJ, Passeri M, Chu LF, Songyang Z, et al. Ronin is essential for embryogenesis and the pluripotency of mouse embryonic stem cells. Cell. 2008;133:1162–74.CrossRefPubMedPubMedCentral

32.

Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell. 2005;122:947–56.CrossRefPubMedPubMedCentral

33.

Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, Takahashi K, et al. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell. 2003;113:631–42.CrossRefPubMed

34.

Loh YH, Wu Q, Chew JL, Vega VB, Zhang W, Chen X, et al. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet. 2006;38:431–40.CrossRefPubMed

35.

Chen X, Xu H, Yuan P, Fang F, Huss M, Vega VB, et al. Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. Cell. 2008;133:1106–17.CrossRefPubMed

36.

Chambers I, Tomlinson SR. The transcriptional foundation of pluripotency. Development. 2009;136:2311–22.CrossRefPubMedPubMedCentral

37.

Wu Q, Chen X, Zhang J, Loh YH, Low TY, Zhang W, et al. Sall4 interacts with Nanog and co-occupies Nanog genomic sites in embryonic stem cells. J Biol Chem. 2006;281:24090–4.CrossRefPubMed

38.

Ishiguro T, Sato A, Ohata H, Sakai H, Nakagama H, Okamoto K. Differential expression of nanog1 and nanogp8 in colon cancer cells. Biochem Biophys Res Commun. 2011;418:199–204.CrossRefPubMed

39.

Bourguignon LY, Spevak CC, Wong G, Xia W, Gilad E. Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J Biol Chem. 2009;284:26533–46.CrossRefPubMedPubMedCentral

40.

Bourguignon LY, Peyrollier K, Xia W, Gilad E. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem. 2008;283:17635–51.CrossRefPubMedPubMedCentral

41.

Zhang J, Wang X, Li M, Han J, Chen B, Wang B, et al. NANOGP8 is a retrogene expressed in cancers. FEBS J. 2006;273:1723–30.CrossRefPubMed

42.

Ambady S, Malcuit C, Kashpur O, Kole D, Holmes WF, Hedblom E, et al. Expression of NANOG and NANOGP8 in a variety of undifferentiated and differentiated human cells. Int J Dev Biol. 2010;54:1743–54.CrossRefPubMedPubMedCentral

43.

Gehring WJ, Qian YQ, Billeter M, Furukubo-Tokunaga K, Schier AF, Resendez-Perez D, et al. Homeodomain-DNA recognition. Cell. 1994;78:211–23.CrossRefPubMed

44.

Jauch R, Ng CK, Saikatendu KS, Stevens RC, Kolatkar PR. Crystal structure and DNA binding of the homeodomain of the stem cell transcription factor Nanog. J Mol Biol. 2008;376:758–70.CrossRefPubMed

45.

Klemm JD, Rould MA, Aurora R, Herr W, Pabo CO. Crystal structure of the Oct-1 POU domain bound to an octamer site: DNA recognition with tethered DNA-binding modules. Cell. 1994;77:21–32.CrossRefPubMed

46.

Phillips K, Luisi B. The virtuoso of versatility: POU proteins that flex to fit. J Mol Biol. 2000;302:1023–39.CrossRefPubMed

47.

Yeom YI, Fuhrmann G, Ovitt CE, Brehm A, Ohbo K, Gross M, et al. Germline regulatory element of Oct-4 specific for the totipotent cycle of embryonal cells. Development. 1996;122:881–94.PubMed

48.

Nordhoff V, Hubner K, Bauer A, Orlova I, Malapetsa A, Scholer HR. Comparative analysis of human, bovine, and murine Oct-4 upstream promoter sequences. Mamm Genome. 2001;12:309–17.CrossRefPubMed

49.

Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N, Lovell-Badge R. Multipotent cell lineages in early mouse development depend on SOX2 function. Genes Dev. 2003;17:126–40.CrossRefPubMedPubMedCentral

50.

Bowles J, Schepers G, Koopman P. Phylogeny of the SOX family of developmental transcription factors based on sequence and structural indicators. Dev Biol. 2000;227:239–55.CrossRefPubMed

51.

Ambrosetti DC, Basilico C, Dailey L. Synergistic activation of the fibroblast growth factor 4 enhancer by Sox2 and Oct-3 depends on protein-protein interactions facilitated by a specific spatial arrangement of factor binding sites. Mol Cell Biol. 1997;17:6321–9.CrossRefPubMedPubMedCentral

52.

Ambrosetti DC, Scholer HR, Dailey L, Basilico C. Modulation of the activity of multiple transcriptional activation domains by the DNA binding domains mediates the synergistic action of Sox2 and Oct-3 on the fibroblast growth factor-4 enhancer. J Biol Chem. 2000;275:23387–97.CrossRefPubMed

53.

Jiang J, Chan YS, Loh YH, Cai J, Tong GQ, Lim CA, et al. A core Klf circuitry regulates self-renewal of embryonic stem cells. Nat Cell Biol. 2008;10:353–60.CrossRefPubMed

54.

Nakatake Y, Fukui N, Iwamatsu Y, Masui S, Takahashi K, Yagi R, et al. Klf4 cooperates with Oct3/4 and Sox2 to activate the Lefty1 core promoter in embryonic stem cells. Mol Cell Biol. 2006;26:7772–82.CrossRefPubMedPubMedCentral

55.

Chew JL, Loh YH, Zhang W, Chen X, Tam WL, Yeap LS, et al. Reciprocal transcriptional regulation of Pou5f1 and Sox2 via the Oct4/Sox2 complex in embryonic stem cells. Mol Cell Biol. 2005;25:6031–46.CrossRefPubMedPubMedCentral

56.

Odom DT, Dowell RD, Jacobsen ES, Nekludova L, Rolfe PA, Danford TW, et al. Core transcriptional regulatory circuitry in human hepatocytes. Mol Syst Biol. 2006;2:2006.0017.CrossRefPubMedPubMedCentral

57.

McBurney MW, Rogers BJ. Isolation of male embryonal carcinoma cells and their chromosome replication patterns. Dev Biol. 1982;89:503–8.CrossRefPubMed

58.

McBurney MW. P19 embryonal carcinoma cells. Int J Dev Biol. 1993;37:135–40.PubMed

59.

Choi SC, Choi JH, Shim WJ, Lim DS. P19 embryonal carcinoma cells: a new model for the study of endothelial cell differentiation. Biotechnol Lett. 2008;30:1169–75.CrossRefPubMed

60.

Liour SS, Kapitonov D, Yu RK. Expression of gangliosides in neuronal development of p19 embryonal carcinoma stem cells. J Neurosci Res. 2000;62:363–73.CrossRefPubMed

61.

Gianakopoulos PJ, Skerjanc IS. Hedgehog signaling induces cardiomyogenesis in P19 cells. J Biol Chem. 2005;280:21022–8.CrossRefPubMed

62.

Bakhshalizadeh S, Esmaeili F, Houshmand F, Shirzad H, Saedi M. Effects of selegiline, a monoamine oxidase B inhibitor, on differentiation of P19 embryonal carcinoma stem cells, into neuron-like cells. In Vitro Cell Dev Biol Anim. 2011;47:550–7.CrossRefPubMed

63.

Xu XS, Hong X, Wang G. Induction of endogenous gamma-globin gene expression with decoy oligonucleotide targeting Oct-1 transcription factor consensus sequence. J Hematol Oncol. 2009;2:15.CrossRefPubMedPubMedCentral

64.

Niwa H, Ogawa K, Shimosato D, Adachi K. A parallel circuit of LIF signalling pathways maintains pluripotency of mouse ES cells. Nature. 2009;460:118–22.CrossRefPubMed

65.

Yang J, Gao C, Chai L, Ma Y. A novel SALL4/OCT4 transcriptional feedback network for pluripotency of embryonic stem cells. PLoS One. 2010;5:e10766.CrossRefPubMedPubMedCentral

66.

Zhang J, Tam WL, Tong GQ, Wu Q, Chan HY, Soh BS, et al. Sall4 modulates embryonic stem cell pluripotency and early embryonic development by the transcriptional regulation of Pou5f1. Nat Cell Biol. 2006;8:1114–23.CrossRefPubMed

67.

Omidi Y, Barar J, Heidari HR, Ahmadian S, Yazdi HA, Akhtar S. Microarray analysis of the toxicogenomics and the genotoxic potential of a cationic lipid-based gene delivery nanosystem in human alveolar epithelial a549 cells. Toxicol Mech Methods. 2008;18:369–78.CrossRefPubMed

68.

Shan J, Shen J, Liu L, Xia F, Xu C, Duan G, et al. Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. Hepatology. 2012;56:1004–14.CrossRefPubMed

69.

Chen WJ, Ho CC, Chang YL, Chen HY, Lin CA, Ling TY, et al. Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling. Nat Commun. 2014;5:3472.PubMed

70.

Pramfalk C, Lanner J, Andersson M, Danielsson E, Kaiser C, Renstrom IM, et al. Insulin receptor activation and down-regulation by cationic lipid transfection reagents. BMC Cell Biol. 2004;5:7.CrossRefPubMedPubMedCentral

71.

Mann MJ, Dzau VJ. Therapeutic applications of transcription factor decoy oligonucleotides. J Clin Invest. 2000;106:1071–5.CrossRefPubMedPubMedCentral

72.

Lu R, Yang A, Jin Y. Dual functions of T-box 3 (Tbx3) in the control of self-renewal and extraembryonic endoderm differentiation in mouse embryonic stem cells. J Biol chem. 2011;286:8425–36.CrossRefPubMed

73.

Hough SR, Clements I, Welch PJ, Wiederholt KA. Differentiation of mouse embryonic stem cells after RNA interference-mediated silencing of OCT4 and Nanog. Stem Cells. 2006;24:1467–75.CrossRefPubMed

74.

Hu G, Kim J, Xu Q, Leng Y, Orkin SH, Elledge SJ. A genome-wide RNAi screen identifies a new transcriptional module required for self-renewal. Genes Dev. 2009;23:837–48.CrossRefPubMedPubMedCentral

Titel: Transcription factor decoy against stem cells master regulators, Nanog and Oct-4: a possible approach for differentiation therapy
verfasst von: Seyed Mohammad Ali Hosseini Rad
Taravat Bamdad
Majid Sadeghizadeh
Ehsan Arefian
Majid Lotfinia
Milad Ghanipour
Publikationsdatum: 01.04.2015
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 4/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-2884-y

Springer Medizin

Transcription factor decoy against stem cells master regulators, Nanog and Oct-4: a possible approach for differentiation therapy

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2015

Knockdown of autophagy-related protein 6, Beclin-1, decreases cell growth, invasion, and metastasis and has a positive effect on chemotherapy-induced cytotoxicity in osteosarcoma cells

Note of clarification of data in the paper entitled no association between XRCC1 gene Arg194Trp polymorphism and risk of lung cancer: evidence based on an updated cumulative meta-analysis

Downregulation of Kruppel-like factor 2 is associated with poor prognosis for nonsmall-cell lung cancer

High CHMP4B expression is associated with accelerated cell proliferation and resistance to doxorubicin in hepatocellular carcinoma

Epigenetic regulation of human hedgehog interacting protein in glioma cell lines and primary tumor samples

Epidermal growth factor receptor variant III renders glioma cancer cells less differentiated by JAGGED1

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie